



GlaxoSmithKline



MERCK SHARP & DOHME

Understanding why Australians with type 2 diabetes are not achieving treatment targets

A report from the research into why many patients with type 2 diabetes are not achieving treatment targets in Australia, conducted for The Pharmaceutical Alliance (Eli Lilly, GlaxoSmithKline and Merck Sharp & Dohme) by TwoBlindMice regarding the existing barriers for clinicians and diabetes educators (Phase I) and patients (Phase II).



The member companies of The Pharmaceutical Alliance; Eli Lilly, GlaxoSmithKline and Merck Sharp & Dohme, have been working together for more than 10 years, and are unique and active in their commitment to Quality Use of Medicines, one of the central objectives of Australia's National Medicines Policy. The Pharmaceutical Alliance has worked on a number of key projects designed to improve the Quality use of Medicines in Australia and will continue to work with the Government and healthcare stakeholders to find better healthcare solutions for Australians.

CONTENTS

| | |
|--|-----------|
| Highlights | 4 |
| Introduction | 5 |
| Methodology | 7 |
| The research findings | 8 |
| Treatment targets in practice | 8 |
| Knowledge of treatment targets | 8 |
| Communication of treatment targets | 8 |
| The importance of clinical manner: authoritarianism and flexibility | 9 |
| Other barriers | 10 |
| Patient barriers | 10 |
| Practitioner barriers | 11 |
| Medical barriers | 11 |
| Systemic barriers | 12 |
| Socio-economic barriers | 13 |
| Recommendations | 14 |
| Conclusions | 14 |
| References | 16 |

